X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

IFRX

Closed

Inflarx N.v.

0.8
0.0 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 0.79
Day's Range: 0.7794 - 0.81
Send
When Written:
 
2.01
InflaRx N.V. is a biopharmaceutical company that focuses on the development of novel therapeutics for the treatment of inflammatory diseases. The company's lead product candidate, IFX-1, is a first-in-class monoclonal antibody that targets the complement system, a key mediator of inflammation. IFX-1 is being developed for the treatment of a range of inflammatory diseases, including hidradenitis suppurativa, ANCA-associated vasculitis, and pyoderma gangrenosum. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. The company went public on the Nasdaq stock exchange in 2017.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X